GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (STU:ANWA) » Definitions » Net Income (Continuing Operations)

Immuron (STU:ANWA) Net Income (Continuing Operations) : €-2.39 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Immuron Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Immuron's Net Income (Continuing Operations) for the six months ended in Dec. 2023 was €-1.27 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.39 Mil.


Immuron Net Income (Continuing Operations) Historical Data

The historical data trend for Immuron's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Net Income (Continuing Operations) Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only -2.86 -1.79 -5.32 -1.90 -2.35

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.15 -0.69 -1.26 -1.12 -1.27

Immuron Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immuron  (STU:ANWA) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Immuron Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Immuron's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron (STU:ANWA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (STU:ANWA) » Definitions » Net Income (Continuing Operations)
Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (STU:ANWA) Headlines

No Headlines